CAR-T therapy – Talk Bio

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

1 month ago talkbio0Tagged CAR-T therapy, CD19 Antigens, CD20 Antigens, Clinical Trials, dual-targeting, Early-stage, Frequency of Responses, J&J, JNJ-4496, Lymphoma, Phase 1b, relapsed/refractory large-B-cell lymphoma

J&J; CAR-T therapy; lymphoma; early-stage; clinical trial; dual-targeting; CD19; CD20; objective response rate; Phase 1b; JNJ-4496; relapsed/refractory large B-cell lymphoma

Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed

4 months ago talkbio0Tagged Adverse effects, analysts, aspects of adverse effects, Autoimmune Diseases, Cabaletta, CAR-T therapy, cell-associated neurotoxicity, Cytokine Release Syndrome, Lupus Erythematosus, Systemic, reSET (device), Systemic Scleroderma

Systemic Scleroderma, Lupus Erythematosus, Systemic, Cabaletta, cell-associated neurotoxicity, Adverse effects, analysts, Autoimmune Diseases, CAR-T therapy, reSET (device), aspects of adverse effects, Cytokine Release Syndrome